APA (7th ed.) Citation

Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortés, J. E., Hughes, T. P., . . . Mauro, M. J. (2023). Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL. Leukemia, 37(3), . https://doi.org/10.1038/s41375-023-01829-9

Chicago Style (17th ed.) Citation

Hochhaus, Andreas, et al. "Asciminib Vs Bosutinib in Chronic-phase Chronic Myeloid Leukemia Previously Treated with at Least Two Tyrosine Kinase Inhibitors: Longer-term Follow-up of ASCEMBL." Leukemia 37, no. 3 (2023). https://doi.org/10.1038/s41375-023-01829-9.

MLA (9th ed.) Citation

Hochhaus, Andreas, et al. "Asciminib Vs Bosutinib in Chronic-phase Chronic Myeloid Leukemia Previously Treated with at Least Two Tyrosine Kinase Inhibitors: Longer-term Follow-up of ASCEMBL." Leukemia, vol. 37, no. 3, 2023, https://doi.org/10.1038/s41375-023-01829-9.